Immunological effects of BRAF+MEK inhibition

References

• Korn EL, Liu PY, Lee SJ, Chapman JA, Niedzwiecki D, Suman VJ, Moon J, Sondak VK, Atkins MB, Eisenhauer EA, et al. Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials. J Clin Oncol. 2008;26(4):527–534. doi:10.1200/JCO.2007.12.7837.
   PubMed Web of Science ®Google Scholar
• Wolchok JD, Chiarion-Sileni V, Gonzalez R, Rutkowski P, Grob JJ, Cowey CL, Lao CD, Wagstaff J, Schadendorf D, Ferrucci PF, et al. Overall survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med. 2017;377(14):1345–1356. doi:10.1056/NEJMoa1709684.
   PubMed Web of Science ®Google Scholar
• Ugurel S, Röhmel J, Ascierto PA, Flaherty KT, Grob JJ, Hauschild A, Larkin J, Long GV, Lorigan P, McArthur GA, et al. Survival of patients with advanced metastatic melanoma: the impact of novel therapies-update 2017. Eur J Cancer. 2017;83:247–257. doi:10.1016/j.ejca.2017.06.028.
   PubMed Web of Science ®Google Scholar
• Ascierto PA, Long GV. Progression-free survival landmark analysis: a critical endpoint in melanoma clinical trials. Lancet Oncol. 2016;17(8):1037–1039. doi:10.1016/S1470-2045(16)30017-1.
   PubMed Web of Science ®Google Scholar
• Da Silveira Nogueira Lima JP, Georgieva M, Haaland B, De Lima Lopes G. A systematic review and network meta-analysis of immunotherapy and targeted therapy for advanced melanoma. Cancer Med. 2017;6(6):1143–1153. doi:10.1002/cam4.1001.
   PubMed Web of Science ®Google Scholar
• Robert C, Kaaszewska B, Schachter J, Rutkowski P, Mackiewicz A, Stroiakovski D, Lichinitser M, Dummer R, Grange F, Mortier L, et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med. 2015;372(1):30–39. doi:10.1056/NEJMoa1412690.
   PubMed Web of Science ®Google Scholar
• Dummer R, Ascierto PA, Gogas HJ, Arance A, Mandala M, Liszkay G, Garbe C, Schadendorf D, Krajsova I, Gutzmer R, et al. Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2018;pii:S1470–2045(18)30142–301426. doi:10.1016/S1470-2045(18)30142-6.
   Google Scholar
• Wilmott JS, Long GV, Howle JR, Haydu LE, Sharma RN, Thompson JF, Kefford RF, Hersey P, Scolyer RA. Selective BRAF inhibitors induce marked T-cell infiltration into human metastatic melanoma. Clin Cancer Res. 2012;18(5):1386–1394. doi:10.1158/1078-0432.CCR-11-2479.
   PubMed Web of Science ®Google Scholar
• Frederick DT, Piris A, Cogdill AP, Cooper ZA, Lezcano C, Ferrone CR, Mitra D, Boni A, Newton LP, Liu C, et al. BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma. Clin Cancer Res. 2013;19(5):1225–1231. doi:10.1158/1078-0432.CCR-12-1630.
   PubMed Web of Science ®Google Scholar
• Hu-Lieskovan S, Mok S, Homet Moreno B, Tsoi J, Robert L, Goedert L, Pinheiro EM, Koya RC, Graeber TG, Comin-Anduix B, et al. Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF (V600E) melanoma. Sci Transl Med. 2015;7(279):279ra41. doi:10.1126/scitranslmed.aaa4691.
   PubMed Web of Science ®Google Scholar
• Schilling B, Paschen A. Immunological consequences of selective BRAF inhibitors in malignant melanoma: neutralization of myeloid-derived suppressor cells. Oncoimmunology. 2013;2(8):e25218. doi:10.4161/onci.25218.
   PubMed Web of Science ®Google Scholar
• Sullivan RJ, Gonzalez R, Lewis KD, Hamid O, Infante JR, Patel MR. Safety and clinical activity of atezolizumab + cobimetinib + vemurafenib in BRAFV600-mutant metastatic melanoma. Paper presented at: Society for Melanoma Research Annual Meeting; 2016 Nov 6–9; Boston, Massachusetts.
   Google Scholar
• Ribas A, Butler M, Lutzky J, Lawrence DP, Robert C, Miller W, Linette GP, Ascierto PA, Kuzel T, Algaziet AP, et al. Phase 1 study combining anti-PD-L1 (MEDI4736) with BRAF (dabrafenib) and/or MEK (trametinib) inhibitors in advanced melanoma. J Clin Oncol. 2015;15(Suppl 15):3003. doi:10.1200/jco.2015.33.15_suppl.3003.
   Google Scholar
• Ribas A, Hodi FS, Lawrence D, Atkinson V, Agarwal S, Carlino MS, Fisher R, Long GV, Miller WH, Huang Y, et al. KEYNOTE-022 update: phase 1 study of first-line pembrolizumab (pembro) plus dabrafenib (D) and trametinib (T) for BRAF-mutant advanced melanoma. Ann Oncol. 2017;28(Suppl 5):v428–v448. doi:10.1093/annonc/mdx377.
   Google Scholar
• Johnpulle RA, Johnson DB, Sosman JA. Molecular targeted therapy approaches for BRAF wild-type melanoma. Curr Oncol Rep. 2016;18(1):6. doi:10.1007/s11912-015-0485-6.
   PubMed Web of Science ®Google Scholar
• Sabbatino F, Wang Y, Scognamiglio G, Favoino E, Feldman SA, Villani V, Flaherty KT, Nota S, Giannarelli D, Simeone E, et al. Antitumor activity of BRAF inhibitor and IFNα combination in BRAF-mutant melanoma. JNCI J Natl Cancer Inst. 2016;108(7). doi:10.1093/jnci/djv435.
   Web of Science ®Google Scholar
• Ascierto PA, McArthur GA. Checkpoint inhibitors in melanoma and early phase development in solid tumors: what’s the future? J Transl Med. 2017;15:173. doi:10.1186/s12967-017-1278-5.
   PubMed Web of Science ®Google Scholar
• Young A, Ngiow SF, Madore J, Reinhardt J, Landsberg J, Chitsazan A, Rautela J, Bald T, Barkauskas DS, Ahern E, et al. Targeting adenosine in BRAF-mutant melanoma reduces tumor growth and metastasis. Cancer Res. 2017;77(17):4684–4696. doi:10.1158/0008-5472.CAN-17-0393.
   PubMed Web of Science ®Google Scholar
• Jang S, Atkins MB. Which drug, and when, for patients with BRAF-mutant melanoma? Lancet Oncol. 2013;14(2):e60–69. doi:10.1016/S1470-2045(12)70539-9.
   PubMed Web of Science ®Google Scholar
• Ascierto PA, Simeone E, Giannarelli D, Grimaldi AM, Romano A, Mozzillo N. Sequencing of BRAF inhibitors and ipilimumab in patients with metastatic melanoma: a possible algorithm for clinical use. J Transl Med. 2012;10:107. doi:10.1186/1479-5876-10-107.
   PubMed Web of Science ®Google Scholar
• Simeone E, Grimaldi AM, Festino L, Giannarelli D, Vanella V, Palla M, Curvietto M, Esposito A, Palmieri G, Mozzillo N, et al. Correlation between previous treatment with BRAF inhibitors and clinical response to pembrolizumab in patients with advanced melanoma. Oncoimmunology. 2017;6(3):e1283462. doi:10.1080/2162402X.2017.1283462.
   PubMed Web of Science ®Google Scholar
• Shoushtari AN, Munhoz RR, Kuk D, Ott PA, Johnson DB, Tsai KK, Rapisuwon S, Eroglu Z, Sullivan RJ, Luke JJ, et al. The efficacy of anti-PD-1 agents in acral and mucosal melanoma. Cancer. 2016;122(21):3354–3362. doi:10.1002/cncr.30259.
   PubMed Web of Science ®Google Scholar
• Blank CU, Haanen JB, Ribas A, Schumacher TN. Cancer immunology. The “cancer immunogram”. Science. 2016;352(6286):658–660. doi:10.1126/science.aaf2834.
   PubMed Web of Science ®Google Scholar
• Massi D, Brusa D, Merelli B, Falcone C, Xue G, Carobbio A, Nassini R, Baroni G, Tamborini E, Cattaneo L, et al. The status of PD-L1 and tumor-infiltrating immune cells predict resistance and poor prognosis in BRAFi-treated melanoma patients harboring mutant BRAFV600. Ann Oncol. 2015;26(9):1980–1987. doi:10.1093/annonc/mdv255.
   PubMed Web of Science ®Google Scholar
• Ascierto PA, Minor DR, Ribas A, Lebbe C, O’Hagan A, Swann RS, Scheuber A, Schadendorf D, Kefford R, Grob JJ, et al. Long-term safety and overall survival update for BREAK-2, a phase 2, single-arm, open-label study of dabrafenib in previously treated metastatic melanoma (NCT01153763). J Clin Oncol. 2014;32(Suppl 15):9034. doi:10.1200/jco.2014.32.15_suppl.9034.
   Web of Science ®Google Scholar
• Chapman PB, Ascierto PA, Schadendorf D, Grob JJ, Ribas A, Kiecke RF. Updated 5-year landmark analyses of phase 2 (BREAK-2) and phase 3 (BREAK-3) studies evaluating dabrafenib monotherapy in patients with BRAF V600–mutant melanoma. J Clin Oncol. 2017;35(Suppl 15):9526. doi:10.1200/JCO.2017.35.15_suppl.9526.
   Google Scholar
• Long GV, Eroglu Z, Infante J, Patel S, Daud A, Johnson DB, Gonzalez R, Kefford R, Hamid O, Schuchter L, et al. Long-term outcomes in patients with BRAF V600–mutant metastatic melanoma who received dabrafenib combined with trametinib. J Clin Oncol. 2017. doi:10.1200/JCO.2017.74.1025.
   Google Scholar
• Robert C, Karaszewska B, Schachter J, Rutkowski P, Mackiewicz A, Stroyakovskiy D, Dummer R, Grange F, Mortier L, Chiarion-Sileni V, et al. Three-year estimate of overall survival in COMBI-v, a randomized phase 3 study evaluating first-line dabrafenib (D) + trametinib (T) in patients (pts) with unresectable or metastatic BRAF V600E/K–mutant cutaneous melanoma. Ann Oncol. 2016;27(Suppl 6):LBA40. doi:10.1093/annonc/mdw435.37.
   Google Scholar
• Yan Y, Robert C, Larkin J, Ascierto PA, Dreno B, Maio M, Garbe C, Chapman PB, Sosman JA, Wongchenko MJ, et al. Genomic features of complete responders (CR) versus fast progressors (PD) in patients with BRAFV600-mutated metastatic melanoma treated with cobimetinib + vemurafenib or vemurafenib alone. Ann Oncol. 2016;27(6):379–400. doi:10.1093/annonc/mdw379.
   PubMedGoogle Scholar
• Larkin J, Lewis KD, Ribas A, Flaherty K, Ascierto PA, Dréno B. Impact of gene expression profiles on clinical predictors of survival in patients with BRAFV600-mutated metastatic melanoma treated with vemurafenib ± cobimetinib. J Clin Oncol. 2017;35(Suppl 15):9556. doi:10.1200/JCO.2017.35.15_suppl.9556.
   Google Scholar
• Schadendorf D, Wolchok JD, Hodi FS, Chiarion-Sileni V, Gonzalez R, Rutkowski P, Grob JJ, Cowey CL, Lao CD, Chesney J, et al. Efficacy and safety outcomes in patients with advanced melanoma who discontinued treatment with nivolumab and ipilimumab because of adverse events: a pooled analysis of randomized phase II and III trials. J Clin Oncol. 2017;35(34):3807–3814. doi:10.1200/JCO.2017.73.2289.
   PubMed Web of Science ®Google Scholar
• Long GV, Atkinson V, Ascierto PA, Robert C, Hassel JC, Rutkowski P, Savage KJ, Taylor F, Coon C, Gilloteau I, et al. Effect of nivolumab on health-related quality of life in patients with treatment-naïve advanced melanoma: results from the phase III CheckMate 066 study. Ann Oncol. 2016;27(10):1940–1946. doi:10.1093/annonc/mdw265.
   PubMed Web of Science ®Google Scholar
• Carlino MS, Vanella V, Girgis C, Giannarelli D, Guminski A, Festino L, Kefford RF, Menzies AM, Long GV, Ascierto PA. Cessation of targeted therapy after a complete response in BRAF-mutant advanced melanoma: a case series. Br J Cancer. 2016;115(11):1280–1284. doi:10.1038/bjc.2016.321.
   PubMed Web of Science ®Google Scholar
• Klein O, Ribas A, Chmielowski B, Walker G, Clements A, Long GV, Kefford RF. Facial palsy as a side effect of vemurafenib treatment in patients with metastatic melanoma. J Clin Oncol. 2013;31(12):e215–217. doi:10.1200/JCO.2012.45.7028.
   PubMed Web of Science ®Google Scholar
• Long GV, Hauschild A, Santinami M, Atkinson V, Mandalà M, Chiarion-Sileni V, Larkin J, Nyakas M, Dutriaux C, Haydon A, et al. Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma. N Engl J Med. 2017;377(19):1813–1823. doi:10.1056/NEJMoa1708539.
   PubMed Web of Science ®Google Scholar
• Amaria R, Prieto PA, Tetzlaff MT, Reuben A, Andrews MC, Ross MI, Glitza IC, Cormier J, Hwu WJ, Tawbi HA, et al. Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial. Lancet. 2018;19(2):181–193. doi:10.1016/S1470-2045(18)30015-9.
   PubMed Web of Science ®Google Scholar
• Wargo JA, Amaria RN, Prieto PA, Andrews MC, Tetzlaff MT, Futreal PA. Relapse-free survival and target identification to enhance response with neoadjuvant and adjuvant dabrafenib + trametinib (D+T) treatment compared to standard-of-care (SOC) surgery in patients (pts) with high-risk resectable BRAF-mutated metastatic melanoma. J Clin Oncol. 2017;35(Suppl 15):9587. doi:10.1200/JCO.2017.35.15_suppl.9587.
   Google Scholar
• Dummer R, Ramelyte E, Schindler S, Thürigen O, Levesque MP, Koelblinger P. MEK inhibition and immune responses in advanced melanoma. Oncoimmunology. 2017;6(8):e1335843. doi:10.1080/2162402X.2017.1335843.
   PubMed Web of Science ®Google Scholar
• Boshuizen J, Koopman LA, Krijgsman O, Shahrabi A, Van Den Heuvel EG, Ligtenberg MA, Vredevoogd DW, Kemper K, Kuilman T, Song JY, et al. Cooperative targeting of melanoma heterogeneity with an AXL antibody-drug conjugate and BRAF/MEK inhibitors. Nat Med. 2018;24(2):203–212. doi:10.1038/nm.4472.
   PubMed Web of Science ®Google Scholar